Metformin as fetal hemoglobin inducer in non-transfusion-dependent thalassemia patients /
Shareef Karam Ali Easa
Metformin as fetal hemoglobin inducer in non-transfusion-dependent thalassemia patients / ميتفورمين" كمحفز للهيموغلوبين الجنينى فى مرضى أنيميا البحر الأبيض المتوسط غير المعتمدين على نقل الدم Shareef Karam Ali Easa ; Supervised Mona Hassan Eltagui , Mona Kamal Elghamrawy , Mariam Saad Soliman - Cairo : Shareef Karam Ali Easa , 2021 - 103 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
Background: Metformin was reported as a potential fetal hemoglobin (HbF) inducing agent but its efficacy and safety in Non-Transfusion-Dependent Thalassemia (NTDT) patients were not fully studied. Objectives: A prospective interventional study aimed to study the effect of metformin on HbF change in NTDT and its role in ameliorating disease severity. Methods: Forty-two patients with established diagnosis of NTDT aged 12-23 years old were enrolled. They were receiving a stable dose of Hydroxyurea (HU) over the last 3 months. Inclusion criteria:- Confirmed diagnosis of NTDT based on hemoglobin Electrophoresis and/or high performance liquid Chromatography .- Age greater than or equal to 12 years of age.- Stable dose of HU over the last 3 months.- Serum creatinine less than or equals to 1.4 mg/dl . - Liver enzymes (ALT and AST) less than or equal to 3 times upper limits of normal .- Patients/ parents giving willingly informed consents Exclusion Criteria: - Simple or chronic red blood cell transfusion therapy in the last 3 months.- Patients with diabetes mellitus who are receiving other anti-diabetic medications.- Patients with chronic hypoxemic conditions associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary diseases
HbF inducers Metformin Non-transfusion dependent Thalassemia
Metformin as fetal hemoglobin inducer in non-transfusion-dependent thalassemia patients / ميتفورمين" كمحفز للهيموغلوبين الجنينى فى مرضى أنيميا البحر الأبيض المتوسط غير المعتمدين على نقل الدم Shareef Karam Ali Easa ; Supervised Mona Hassan Eltagui , Mona Kamal Elghamrawy , Mariam Saad Soliman - Cairo : Shareef Karam Ali Easa , 2021 - 103 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
Background: Metformin was reported as a potential fetal hemoglobin (HbF) inducing agent but its efficacy and safety in Non-Transfusion-Dependent Thalassemia (NTDT) patients were not fully studied. Objectives: A prospective interventional study aimed to study the effect of metformin on HbF change in NTDT and its role in ameliorating disease severity. Methods: Forty-two patients with established diagnosis of NTDT aged 12-23 years old were enrolled. They were receiving a stable dose of Hydroxyurea (HU) over the last 3 months. Inclusion criteria:- Confirmed diagnosis of NTDT based on hemoglobin Electrophoresis and/or high performance liquid Chromatography .- Age greater than or equal to 12 years of age.- Stable dose of HU over the last 3 months.- Serum creatinine less than or equals to 1.4 mg/dl . - Liver enzymes (ALT and AST) less than or equal to 3 times upper limits of normal .- Patients/ parents giving willingly informed consents Exclusion Criteria: - Simple or chronic red blood cell transfusion therapy in the last 3 months.- Patients with diabetes mellitus who are receiving other anti-diabetic medications.- Patients with chronic hypoxemic conditions associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary diseases
HbF inducers Metformin Non-transfusion dependent Thalassemia